Legacy Wealth Management LLC MS Sells 8,935 Shares of IQVIA Holdings Inc. $IQV

Legacy Wealth Management LLC MS decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 53.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,752 shares of the medical research company’s stock after selling 8,935 shares during the quarter. Legacy Wealth Management LLC MS’s holdings in IQVIA were worth $1,498,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC lifted its position in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA during the second quarter valued at $514,000. First Trust Advisors LP grew its holdings in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV stock opened at $237.97 on Friday. The firm has a market cap of $39.17 billion, a price-to-earnings ratio of 29.53, a PEG ratio of 2.03 and a beta of 1.18. The company’s 50 day moving average is $200.92 and its 200 day moving average is $186.95. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $251.36.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the business earned $2.81 earnings per share. IQVIA’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IQV shares. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Royal Bank Of Canada boosted their price target on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. raised their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock worth $3,098,793 in the last three months. 1.70% of the stock is owned by company insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.